Michael J Gough

List of Publications by Year in Descending Order

95 papers	4,153 citations	40 h-index	62 g-index
123 ext. papers	4,912 ext. citations	6.2 avg, IF	5.23 L-index

#	Paper	IF	Citations
95	Defining Immunogenic and Radioimmunogenic Tumors. *Frontiers in Oncology*, **2021**, 11, 667075	5.3	7
94	The Dynamic Entropy of Tumor Immune Infiltrates: The Impact of Recirculation, Antigen-Specific Interactions, and Retention on T Cells in Tumors. *Frontiers in Oncology*, **2021**, 11, 653625	5.3	4
93	Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma **2021**, 9,		16
92	Explant Modeling of the Immune Environment of Head and Neck Cancer. *Frontiers in Oncology*, **2021**, 11, 611365	5.3	2
91	A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection. *Oncotarget*, **2021**, 12, 1201-1213	3.3	1
90	Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. *Cancer Immunology, Immunotherapy*, **2021**, 70, 989-1000	7.4	10
89	Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer. *OncoImmunology*, **2021**, 10, 1900635	7.2	15
88	Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer. *Cancer Research*, **2021**, 81, 3255-3269	10.1	9
87	Listeria monocytogenes-infected human monocytic derived dendritic cells activate V□V□ T cells independently of HMBPP production. *Scientific Reports*, **2021**, 11, 16347	4.9	0
86	Dendritic Cell Maturation Defines Immunological Responsiveness of Tumors to Radiation Therapy. *Journal of Immunology*, **2020**, 204, 3416-3424	5.3	23
85	Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2020**, 108, 93-103	4	10
84	Using Preclinical Data to Design Combination Clinical Trials of Radiation Therapy and Immunotherapy. *Seminars in Radiation Oncology*, **2020**, 30, 158-172	5.5	4
83	Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity. *Scientific Reports*, **2020**, 10, 7376	4.9	22
82	TGF□suppresses CD8 T cell expression of CXCR3 and tumor trafficking. *Nature Communications*, **2020**, 11, 1749	17.4	45
81	Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner. *Frontiers in Immunology*, **2020**, 11, 1430	8.4	1
80	Transcriptional and immunohistological assessment of immune infiltration in pancreatic cancer. *PLoS ONE*, **2020**, 15, e0238380	3.7	5
79	Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma. *PLoS ONE*, **2019**, 14, e0211117	3.7	32

78	Abstract CT182: Neoadjuvant immuno-radiotherapy (NIRT) in head and neck cancer: Phase I/Ib study of combined PD-1/SBRT prior to surgical resection **2019**,		3
77	A microbial-based cancer vaccine for induction of EGFRvIII-specific CD8+ T cells and anti-tumor immunity. *PLoS ONE*, **2019**, 14, e0209153	3.7	10
76	Activating the Nucleic Acid-Sensing Machinery for Anticancer Immunity. *International Review of Cell and Molecular Biology*, **2019**, 344, 173-214	6	15
75	Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity. *Scientific Reports*, **2018**, 8, 7012	4.9	56
74	Association of Immunologic Markers With Survival in Upfront Resectable Pancreatic Cancer. *JAMA Surgery*, **2018**, 153, 1055-1057	5.4	9
73	Amplifying IFN-β Signaling in Dendritic Cells by CD11c-Specific Loss of SOCS1 Increases Innate Immunity to Infection while Decreasing Adaptive Immunity. *Journal of Immunology*, **2018**, 200, 177-185	5.3	8
72	Role of the immunosuppressive microenvironment in immunotherapy. *Advances in Radiation Oncology*, **2018**, 3, 520-526	3.3	61
71	Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma. *Cancer Research*, **2018**, 78, 6308-6319	10.1	35
70	A Novel Agonist of the TRIF Pathway Induces a Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses. *MBio*, **2017**, 8,	7.8	27
69	Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control. *International Journal of Radiation Oncology Biology Physics*, **2017**, 99, 362-373	4	31
68	Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. *Clinical Cancer Research*, **2017**, 23, 6165-6177	12.9	179
67	Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma. *Hepatology Research*, **2017**, 47, 702-714	5.1	30
66	STING expression and response to treatment with STING ligands in premalignant and malignant disease. *PLoS ONE*, **2017**, 12, e0187532	3.7	23
65	Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model. *Oncotarget*, **2017**, 8, 9155-9173	3.3	41
64	The TAM family as a therapeutic target in combination with radiation therapy. *Emerging Topics in Life Sciences*, **2017**, 1, 493-500	3.5	3
63	A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma **2016**, 4, 45		60
62	Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy. *Oral Oncology*, **2016**, 61, 166-76	4.4	9
61	OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment. *Oral Oncology*, **2016**, 52, 1-10	4.4	41

60	Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors. *Cancer Research*, **2016**, 76, 50-61	10.1	146
59	Preclinical combination of radiation and fibroblast activation protein inhibition in pancreatic cancer.. *Journal of Clinical Oncology*, **2016**, 34, e23117-e23117	2.2	1
58	Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy. *PLoS ONE*, **2016**, 11, e0157164	3.7	171
57	Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy. *Oncotarget*, **2016**, 7, 78653-78666	3.3	61
56	Stromal fibroblasts support dendritic cells to maintain IL-23/Th17 responses after exposure to ionizing radiation. *Journal of Leukocyte Biology*, **2016**, 100, 381-9	6.5	13
55	Tumor immune remodeling by TGF□nhibition improves the efficacy of radiation therapy. *OncoImmunology*, **2015**, 4, e955696	7.2	6
54	Comparing equals when evaluating immunotherapy with different doses and fractions of radiation therapy. *Immunotherapy*, **2015**, 7, 847-9	3.8	9
53	Developing an Immunotherapy Strategy for the Effective Treatment of Oral, Head and Neck Squamous Cell Carcinoma. *Journal of Oral and Maxillofacial Surgery*, **2015**, 73, S107-15	1.8	3
52	Circulating immune cells in patients with surgically resected nonfunctional pancreatic neuroendocrine tumors **2015**, 3, P140		78
51	Tumor control by intravenous administration of STING ligand requires combination with precisely timed radiation therapy **2015**, 3,		78
50	Programmed cell death-1 blockade in combination with stereotactic radiation in an orthotopic mouse model of hepatocellular carcinoma **2015**, 3, P369		78
49	Radiation therapy and vaccination against tumor-specific EGFRvIII effectively clears tumors in a murine model of head and neck squamous cell carcinoma **2015**, 3,		78
48	Ideal Timing of Immunotherapy With Radiation in Murine Tumor Models. *International Journal of Radiation Oncology Biology Physics*, **2014**, 90, S58	4	3
47	Intratumoral injection of STING ligand promotes abscopal effect **2014**, 2,		78
46	Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy **2014**, 2,		78
45	Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice. *Radiation Research*, **2014**, 182, 182-90	3.1	31
44	TGF□nhibition prior to hypofractionated radiation enhances efficacy in preclinical models. *Cancer Immunology Research*, **2014**, 2, 1011-22	12.5	40
43	Circulating and intratumoral macrophages in patients with hepatocellular carcinoma: correlation with therapeutic approach. *American Journal of Surgery*, **2013**, 205, 534-40	2.7	4

42	The ataxia telangiectasia mutated kinase pathway regulates IL-23 expression by human dendritic cells. *Journal of Immunology*, **2013**, 190, 3246-55	5.3	18
41	Immune consequences of CT-guided radiation therapy of mouse mammary tumors **2013**, 1,		78
40	Improved efficacy of radiation in combination with TGF inhibition in a colorectal cancer mouse model **2013**, 1,		78
39	The impact of the myeloid response to radiation therapy. *Clinical and Developmental Immunology*, **2013**, 2013, 281958		34
38	An exploratory phase I trial of immunochemoradiotherapy in locally advanced and borderline resectable (LA/BR) pancreatic adenocarcinoma (PC).. *Journal of Clinical Oncology*, **2013**, 31, 174-174	2.2	1
37	The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor. *PLoS ONE*, **2013**, 8, e69527	3.7	34
36	Targeting macrophages in the tumour environment to enhance the efficacy of OX40 therapy. *Immunology*, **2012**, 136, 437-47	7.8	19
35	Expression of NF-B p50 in tumor stroma limits the control of tumors by radiation therapy. *PLoS ONE*, **2012**, 7, e39295	3.7	71
34	Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. *Journal of Immunotherapy*, **2010**, 33, 798-809	5	121
33	Signaling through OX40 enhances antitumor immunity. *Seminars in Oncology*, **2010**, 37, 524-32	5.5	107
32	Combination approaches to immunotherapy: the radiotherapy example. *Immunotherapy*, **2009**, 1, 1025-37	3.8	26
31	Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. *European Journal of Immunology*, **2009**, 39, 2184-94	6.1	44
30	OX40 (CD134) and OX40L. *Advances in Experimental Medicine and Biology*, **2009**, 647, 94-107	3.6	27
29	Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo **2009**, 39, 2184		1
28	OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. *Cancer Research*, **2008**, 68, 5206-15	10.1	124
27	Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells. *Gene Therapy*, **2007**, 14, 998-1009	4	17
26	Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. *Journal of Immunology*, **2007**, 179, 7244-53	5.3	74
25	Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. *Gene Therapy*, **2006**, 13, 138-49	4	42

24	Intratumoral immunotherapy: using the tumour against itself. *Immunology*, **2005**, 114, 11-22	7.8	56
23	Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. *Journal of Immunology*, **2005**, 174, 5766-73	5.3	51
22	MIP-3alpha transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. *Journal of Immunology*, **2004**, 173, 4929-35	5.3	40
21	A simple method to cure established tumors by inflammatory killing of normal cells. *Nature Biotechnology*, **2004**, 22, 1125-32	44.5	97
20	Induction of cell stress through gene transfer of an engineered heat shock transcription factor enhances tumor immunogenicity. *Gene Therapy*, **2004**, 11, 1099-104	4	12
19	Facets of heat shock protein 70 show immunotherapeutic potential. *Immunology*, **2003**, 110, 1-9	7.8	92
18	A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. *Nature Medicine*, **2003**, 9, 1215-9	50.5	63
17	Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells. *Cancer Research*, **2003**, 63, 2145-9	10.1	35
16	Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. *Cancer Research*, **2003**, 63, 5505-12	10.1	48
15	Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. *Nature Biotechnology*, **2002**, 20, 256-63	44.5	28
14	Dendritic cells for the immunotherapy of cancer. *Clinical Oncology*, **2002**, 14, 185-92	2.8	5
13	Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery?. *Human Gene Therapy*, **2002**, 13, 1263-80	4.8	69
12	Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. *Cancer Research*, **2002**, 62, 5495-504	10.1	67
11	Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. *Cancer Research*, **2002**, 62, 6566-78	10.1	74
10	Renal carcinoma cell lines inhibit natural killer activity via the CD94 receptor molecule. *Cancer Immunology, Immunotherapy*, **2001**, 50, 260-8	7.4	11
9	A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component. *Gene Therapy*, **2001**, 8, 987-98	4	30
8	Cell death associated with genetic prodrug activation therapy of colorectal cancer. *Cancer Letters*, **2001**, 174, 25-33	9.9	16
7	Macrophages orchestrate the immune response to tumor cell death. *Cancer Research*, **2001**, 61, 7240-7	10.1	56

6	PKC-delta is an apoptotic lamin kinase. *Oncogene*, **2000**, 19, 2331-7	9.2	190
5	Apoptosis or necrosis for tumor immunotherapy: what is in a name?. *Journal of Molecular Medicine*, **1999**, 77, 824-33	5.5	87
4	The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis--preliminary findings. *Electrophoresis*, **1999**, 20, 689-700	3.6	271
3	Does osmotic control of gastric emptying persist after truncal vagotomy?. *British Journal of Surgery*, **1981**, 68, 77-80	5.3	8
2	Bile reflux and gastric emptying in patients with combined gastric and duodenal ulceration. *British Journal of Surgery*, **1981**, 68, 323-5	5.3	1
1	The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis Preliminary findings109-120		